Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

[Prueba de un dispositivo que no está aprobado ni autorizado por la FDA de EE. UU.] (INNOVATE)

3 de noviembre de 2026 actualizado por: BrioHealth Solutions, Inc.

The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

Descripción general del estudio

Descripción detallada

The INNOVATE Trial is a prospective, non-blinded, randomized, controlled, multi-center, non-inferiority study to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3™ (HM3) LVAS (Abbott) when used for the treatment of advanced, refractory left ventricular heart failure. It is the first clinical study to compare two left ventricular assist devices (LVAD) that belong to the same category of fully magnetically levitated LVAD.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

780

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • University of Alabama at Birmingham Hospital
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • Baptist Health Medical Center-Little Rock
    • California
      • Los Angeles, California, Estados Unidos, 90048
        • Cedars-Sinai Medical Center
    • Florida
      • Gainsville, Florida, Estados Unidos, 32608
        • UF Health Shands Hospital
      • Orlando, Florida, Estados Unidos, 32803
        • Advent Health
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Emory University
      • Atlanta, Georgia, Estados Unidos, 30309
        • Piedmont Healthcare
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Northwestern University
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago
      • Chicago, Illinois, Estados Unidos, 60453
        • Advocate Christ Medical Center
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46260
        • Ascension St. Vincent Hospital - Indianapolis
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • The University Of Kansas Medical Center
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40536
        • University of Kentucky
      • Louisville, Kentucky, Estados Unidos, 40202
        • University of Louisville
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • University of Maryland Medical Center
      • Baltimore, Maryland, Estados Unidos, 21287
        • The Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Estados Unidos, 02111
        • Tufts Medical Center
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan
      • Detriot, Michigan, Estados Unidos, 48202
        • Henry Ford Health
      • Grand Rapids, Michigan, Estados Unidos, 49503
        • Corewell Health Grand Rapids Hospital
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • University of Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55407
        • Abbott Northwestern Hospital
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • WashU Medicine
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68198
        • University of Nebraska Medical Center
    • New Jersey
      • Newark, New Jersey, Estados Unidos, 07112
        • Newark Beth Israel Medical Center
    • New York
      • New York, New York, Estados Unidos, 10065
        • Weill Cornell Medicine
      • New York, New York, Estados Unidos, 10016
        • NYU Langone Health
      • New York, New York, Estados Unidos, 10029
        • Mount Sinai
      • New York, New York, Estados Unidos, 10032
        • Columbia University Irving Medical Center/ New York Presbyterian Hospital
      • The Bronx, New York, Estados Unidos, 10467
        • Montefiore Medical Center
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Duke University
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
        • The Christ Hospital - Cincinnati
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • Thomas Jefferson University Hospital
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Medical University of South Carolina
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38120
        • Baptist - Memphis (Stern)
    • Texas
      • Dallas, Texas, Estados Unidos, 75246
        • Baylor University Medical Center, part of Baylor Scott & White Health
      • Dallas, Texas, Estados Unidos, 75390
        • UT southwestern Medical Center
      • Houston, Texas, Estados Unidos, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Estados Unidos, 77030
        • Memorial Hermann-Texas Medical Center
      • Houston, Texas, Estados Unidos, 77030
        • Texas Heart Institute at Baylor St. Luke's Medical Center
      • Plano, Texas, Estados Unidos, 75093
        • Baylor Scott & White Medical Center - Plano
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84132
        • University of Utah
    • Virginia
      • Falls Church, Virginia, Estados Unidos, 22042
        • Inova Fairfax Medical Campus
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53215
        • Aurora St. Luke's Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 100 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Patient is ≥ 18 years of age.

  2. Patient has received institutional approval for LVAD implantation.

  3. Patient has a body surface area (BSA) ≥ 1.2 m2.

  4. Patient is classified as NYHA Class IV with advanced heart failure refractory to advanced heart failure management or NYHA Class III with dyspnea upon mild physical activity.

  5. Patient has a left ventricular ejection fraction (LVEF) ≤ 25% or LVEF < 30% on inotropes or temporary MCS.

  6. Patient is inotrope dependent, OR has a cardiac index (CI) ≤ 2.2 liters/min/m2, while not on inotropes, and also meets one of the following criteria:

    1. Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or
    2. Has advanced heart failure for at least 14 days and is dependent on an intra-aortic balloon pump (IABP) or temporary mechanical circulatory support device (MCSD) for at least seven days.
  7. Patient has provided voluntary and informed consent.

  8. Females of childbearing age agree to use adequate contraception and have a negative pregnancy test.

Exclusion Criteria:

  1. Patient's heart failure etiology is related to restrictive or constrictive physiology (e.g., nondilated hypertrophic cardiomyopathy, cardiac amyloidosis/senile or other infiltrative disease), complex congenital heart disease (e.g., transposition of the great vessels), uncorrected thyroid disease, and/or pericardial disease.

  2. Patient had a myocardial infarction within seven days of study enrollment.

  3. Patient had cardiothoracic surgery within 30 days of implant with the exception of a procedure to implant temporary MCS: Impella 5.5, Impella CP or TandemHeart.

  4. Patient has physiological conditions or comorbidities which pose high surgical risk or obstacles as determined by the Investigator.

  5. Patient has contraindications to warfarin anticoagulation.

  6. Patient has known hypo- or hypercoagulable state [e.g., disseminated intravascular coagulation (DIC)], or has a positive heparin-induced thrombocytopenia (HIT) assay and positive serotonin release assay or requires use of a non-heparin alternative anticoagulation strategy for cardiopulmonary bypass in the judgement of the Investigator.

  7. Patient is on durable MCS (e.g., LVAD or RVAD).

  8. Planned need for durable or temporary RVAD support concomitant with LVAD implant.

  9. Patient is on any form of pre-implant temporary MCS other than isolated LVAD support with an intra-aortic balloon pump, Impella 5.5, Impella CP, or TandemHeart.

  10. Patient is on any form of pre-implant temporary MCS and has a serum lactate dehydrogenase greater than 2.5 times the upper limits of normal or plasma free hemoglobin > 40 g/dL.

  11. Patient has a history of organ transplantation.

  12. Patient has a mechanical aortic valve that may not be converted to a bioprosthetic valve at the time of VAD implant.

  13. Patient has a platelet count < 50 k/μl.

  14. Patient has a history of confirmed untreated abdominal aortic aneurysm (AAA) > 5 cm in diameter.

  15. Patient has moderate or severe aortic insufficiency that will not be corrected during the VAD implant procedure.

  16. Patient has an uncontrolled systemic infection.

  17. Patient has a positive COVID 19 test within 21 days of study enrollment and at least one high risk feature including need for supplemental oxygen or ferritin >1000 ug/L.

  18. Patient has severe end-organ dysfunction as evidenced by one or more of the following criteria:

    1. Total bilirubin > 3.0 mg/dL or cirrhosis confirmed by liver imaging or hemodynamic assessment with or without biopsy confirmation.
    2. International normalized ratio (INR) ≥ 2.0 or PTT > 2.5 times control that is not related to anticoagulation therapy.
    3. Glomerular filtration rate (GFR) < 30 mL/ min/1.73 m2 or need for renal replacement therapy.
    4. Severe pulmonary arterial hypertension with a pulmonary vascular resistance (PVR) ≥ 8 Wood units that is not acutely reversible with pharmacologic intervention.
    5. Severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease requiring home oxygen or an FEV1/FVC < 0.7 and FEV1 < 40% predicted.
    6. Mechanical ventilation for more than three days present at the time of study enrollment.
    7. Documented history of pulmonary embolism or pulmonary infarct within 60 days of study enrollment.
    8. History of stroke within 90 days of study enrollment or history of stroke with a mRS ≥ 3 at the time of study enrollment.
    9. Symptomatic cerebrovascular disease and/or uncorrected carotid stenosis > 80%.
    10. Significant peripheral vascular disease (PVD) accompanied by pain at rest or extremity ulceration.
    11. Pre-albumin < 15 mg/dL and/or albumin < 2.5 g/dL.
  19. Patient has a non-cardiac comorbidity or illness that would limit survival to less than two years.

  20. Patient has a psychiatric disease or disorder, or irreversible cognitive dysfunction, and/or insufficient social support or a history of non-adherence with medical instructions that is likely to impair study compliance.

  21. Patient is participating in an interventional clinical trial that may impact or confound the results of the INNOVATE Trial.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: BrioVAD System

BrioVAD® Left Ventricular Assist System (BrioVAD® System) by BrioHealth Solutions, Inc.

Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure.

Comparador activo: HeartMate 3

HeartMate 3 System by Abbott

Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Short-Term Indication Primary Endpoint
Periodo de tiempo: 6 months

Composite of survival to transplant, recovery or 6 months of LVAD support free of debilitating stroke [modified Rankin Scale (mRS) > 3], or reoperation to replace the pump

6 months
Long-Term Indication Primary Endpoint
Periodo de tiempo: 24 months

Composite of survival to transplant, recovery or 24 months of LVAD support free of debilitating stroke (mRS > 3), or reoperation to replace the pump.

24 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Powered Secondary Endpoint
Periodo de tiempo: 24 months

Total number of nights in hospital, skilled nursing facility, or inpatient rehabilitation, inclusive of index hospitalization, through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first.

24 months
Short-Term Indication Secondary Endpoint
Periodo de tiempo: 6 months

Evaluation of the short-term safety using INTERMACS adverse event (AE) terms and definitions through 6 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 6 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. Serious adverse events (SAEs) will be analyzed in a similar manner.

6 months
Long-Term Indication Secondary Endpoint
Periodo de tiempo: 24 months

Evaluation of the long-term safety using INTERMACS AE terms and definitions through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 24 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. SAEs will be analyzed in a similar manner

24 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

28 de octubre de 2024

Finalización primaria (Estimado)

1 de febrero de 2028

Finalización del estudio (Estimado)

1 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

7 de marzo de 2024

Primero enviado que cumplió con los criterios de control de calidad

7 de marzo de 2024

Publicado por primera vez (Actual)

13 de marzo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

Protocol and data is company confidential.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir